CHO-PD-L1 Cells

Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. If you represent a commercial entity or are unsure which category applies, please
contact us.

CHO-PD-L1 cells are recombinant Chinese hamster ovary (CHO) cells engineered to stably express human programmed death-ligand 1 (PD-L1; CD274/B7-H1), an immune checkpoint ligand that plays a central role in suppression of T-cell-mediated immune responses. PD-L1 is a type I transmembrane protein that interacts primarily with programmed cell death protein 1 (PD-1/CD279) on activated immune cells, leading to inhibition of T-cell proliferation, cytokine production, and cytotoxic activity. Aberrant PD-L1 expression is a common mechanism of immune evasion in multiple solid tumors and hematologic malignancies, making PD-L1-expressing recombinant cell models highly relevant for immuno-oncology research and therapeutic development.

CHO-PD-L1 cells are widely used for the development and characterization of immune checkpoint inhibitors, including monoclonal antibodies, bispecific antibodies, fusion proteins, and engineered cell therapies targeting the PD-1/PD-L1 signaling axis. The stable and controlled expression of PD-L1 enables quantitative evaluation of antibody binding affinity, receptor occupancy, blocking activity, internalization, and ligand-receptor interaction kinetics. These cells are also suitable for flow cytometry assay development, reporter bioassays, T-cell activation studies, and high-throughput screening platforms designed to assess checkpoint blockade efficacy or immune synapse formation. Because CHO cells provide a robust and relatively low-background expression system, they are frequently selected for standardized assay generation and biologic quality control applications.